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Abstract
Introduction: Oral pre-exposure prophylaxis (PrEP) is a promising new prevention approach for those most at risk of HIV
infection. However, there are concerns that behavioural disinhibition, specifically reductions in condom use, might limit
PrEP’s protective effect. This study uses the case of female sex workers (FSWs) in Johannesburg, South Africa, to assess
whether decreased levels of condom use following the introduction of PrEP may limit HIV risk reduction.
Methods: We developed a static model of HIV risk and compared HIV-risk estimates before and after the introduction of
PrEP to determine the maximum tolerated reductions in condom use with regular partners and clients for HIV risk not to
change. The model incorporated the effects of increased STI exposure owing to decreased condom use. Noting that condom
use with regular partners is generally low, we also estimated the change in condom use tolerated with clients only, to still
achieve 50 and 90% risk reduction on PrEP. The model was parameterized using data from Hillbrow, Johannesburg. Sensitivity
analyses were performed to ascertain the robustness of our results.
Results: Reductions in condom use could be tolerated by FSWs with lower baseline condom use (65%). For scenarios where
75% PrEP effectiveness is attained, 50% HIV-risk reduction on PrEP would be possible even with 100% reduction in condom
use from consistent condom use as high as 70% with clients. Increased exposure to STIs through reductions in condom use
had limited effect on the reductions in condom use tolerated for HIV risk not to increase on PrEP.
Conclusions: PrEP is likely to be of benefit in reducing HIV risk, even if reductions in condom use do occur. Efforts to promote
consistent condom use will be critical for FSWs with high initial levels of condom use, but with challenges in adhering to
PrEP.
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compensation; condom migration
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Introduction
Oral pre-exposure prophylaxis (PrEP) is a promising
approach to HIV prevention. It is hoped that PrEP might
become an effective addition to combined HIV prevention
and help to significantly reduce HIV risk for vulnerable
groups. This would be especially critical for those popula-
tions with low ability to negotiate condom use due to
gender and societal power imbalances, such as young
women in heterosexual relationships [1] and sex workers
[2]. Proof of concept has been demonstrated [3] in four out
of the six randomized controlled trials conducted to date, in
which higher levels of HIV-risk reduction were associated
with higher levels of adherence. Open-label extension
studies [3–6] have confirmed PrEP’s importance as a pre-
vention tool, with up to 100% risk reduction estimated in
the Open Label Extension (OLE) of the iPrEx trial [7] for men
and transgender women who have sex with men adhering
to PrEP for at least four out of seven doses a week.
Nonetheless, the two randomized controlled trials [8,9]
stopped early for futility cited lack of adherence by the
study populations as the cause. Additional implementation
concerns have been raised, including antiretroviral (ARV)
resistance development resulting from sub-optimal drug
adherence levels [10], contraindications [11], challenges in
acceptability [12], barriers to access and programme reten-
tion [13], and behaviour change [14–18]. Noting both the
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positive trial results as well as implementation concerns, in
July 2012 the World Health Organisation (WHO) [19] called
for countries to undertake demonstration projects to gain
insight into acceptability, patterns of use, and sustainability
of PrEP.
Data since gathered has informed WHO’s September
2015 PrEP guidance [19] recommending oral PrEP for all
people at substantial risk of HIV (incidence >3 per 100
person years). However, concerns remain [20–24] regarding
the potential limiting effects of a particular form of beha-
viour change – reductions in condom use (condom migra-
tion) – on PrEP. Reductions in condom use not only
increase the chance of HIV exposure, but also the exposure
to and transmission of sexually transmitted infections
(STIs). Increased exposure to STIs increases both the sus-
ceptibility of an HIV negative partner, as well as the infec-
tiousness of an HIV positive partner, and thereby HIV
transmission [25]. Whilst no trial to date has reported
decreased condom use, the high rate of pregnancies
reported in the trials [12], results of behavioural surveys
[26] and qualitative research [13] indicate that efforts to
tackle condom migration may need to be considered in the
design of PrEP programmes.
In response to these concerns and to inform PrEP pro-
gramme design, this study examines the extent to which
condom migration is likely to impact PrEP effectiveness in
programmes for female sex workers (FSWs). We focus on
the FSW population working in Hillbrow, Johannesburg,
some of whom are participating in a PrEP demonstration
programme undertaken by the Wits Reproductive Health
and HIV Institute (WRHI) [27]. The FSW populations in this
setting present extremely high baseline HIV prevalence
(estimated to be up to 72% [28,29]), elevated levels of
STIs [30] low levels of condom use with often high HIV
risk [31] regular partners, and known challenges in condom
negotiation with clients, where in such settings FSWs may
receive a quarter of the average price for transactional sex
if condoms are insisted upon [17].
Our study aims to inform rapidly changing policy in South
Africa where in November 2015, South Africa’s Medicines
Control Council approved the use of the fixed-dose combi-
nation of TDF/FTC as PrEP [32]. Locally adapted guidelines
[33] were published in early 2016 and PrEP was recently
included in South Africa’s National Sex Worker HIV Plan
(2016–2019) [34]. PrEP roll out for sex workers started in
June 2016.
Methods
This work builds on that in [35], where an adaption of an
HIV-risk equation was used to assess microbicides as a new
HIV prevention method. This study uses the established
Bernoulli model of HIV transmission [36–39] where the
probability of the HIV virus being transmitted through
each sexual contact is treated as an independent risk
event. We employed static rather than dynamic mathema-
tical modelling to obtain clear deductions regarding the
contribution of the parameters being explored to HIV risk,
and for the derivation of rules of thumb that can be broadly
understood and applied to HIV prevention efforts focused
on FSWs. Whilst previous studies [37,40,41] have used
mathematical modelling to predict the impact of condom
migration on the effectiveness of ARV-based microbicides,
this is the first study to consider its impact on oral PrEP, in
particular for FSWs.
The HIV risk equations for a population of HIV-negative
FSWs and their partners prior to, and following introduction
of, PrEP are outlined in the Supplementary Methods. To
explore the consequences for FSWs of condom migration
on PrEP, condoms are assumed to be used with consistency
that may vary with the introduction of PrEP (γ0 prior to
PrEP introduction and γ1 after its introduction). We
assumed condoms to have an HIV risk reduction efficacy; ε,
including slippage and breakage. Whilst the risk reduction
effectiveness of condoms is generally assumed to follow a
linear relationship between use and efficacy (εγÞ, the exact
effectiveness relationship between adherence and PrEP
efficacy remains under investigation [42–44] (although
one study suggested a linear relationship [45]), so we
assume an overall level of “PrEP effectiveness”, bα, corre-
sponding to a level of FSW PrEP adherence, α. No partner
populations are assumed to be taking PrEP.
Single partner population
We started the analysis by considering a single partner
population, in whom the proportion HIV positive is p. For
a given time period, a FSW is assumed to have n partners,
each with whom she has an average of m sex acts. For
simplicity these equations assume an overall average prob-
ability of HIV transmission, β, per sexual contact with an
HIV-positive partner.
We used the HIV risk equations to derive two key thresh-
old conditions: (1) the level of PrEP effectiveness that must
be attained for PrEP to be of benefit in reducing HIV risk,
considering any change in condom consistency; and (2) the
“break-even” level of condom consistency after introduc-
tion of PrEP such that HIV acquisition risk is not increased.
Single partner population, accounting for increased STI
exposure
We expanded our analysis to explore the increased risk of
HIV transmission resulting from exposure to STIs, should
condom migration occur and PrEP use be inconsistent. s is
taken as the probability that at least one person in the
partnership has an STI, and δ the multiplicative increase in
per sex act probability of HIV transmission in the presence
of an STI.
We derived the percentage reduction in condom consis-
tency tolerated for HIV risk not to increase on PrEP and
compared these results to those not accounting for
increased STI exposure, to see whether conclusions remain
robust.
Two partner populations, accounting for increased STI
exposure
We then extended the HIV-risk equations to account for
risk arising from two distinct partner populations: cli-
ents cð Þ and regular partners rð Þ. In this setting, condom
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consistency with regular partners is low [46] and clients
sometimes pay more for condom-less sex [47]. As such,
any change in condom consistency on PrEP is likely to
be more profound with clients, and therefore its impact
on HIV risk. We thus examined the percentage reduc-
tion in condom consistency with clients tolerated for
HIV risk not to increase on PrEP, holding condom con-
sistency with regular partners constant (using
Supplementary Materials equations S14 and S15). We
assessed whether the results remain the same, account-
ing or not for increased STI exposure through decreased
condom use. To gauge whether, in such settings,
changes in condom use with clients or regular partners
present the biggest HIV risk, we assessed whether there
is a significant difference in the percentage reduction in
condom consistency with clients tolerated for HIV risk
not to increase, if PrEP use reduces condom use to zero
with regular partners.
The equations were solved numerically using Solver in
Microsoft Excel 2013 (set to perform 10,000 iterations per
calculation) to ascertain the maximum change in condom
consistency that can be tolerated for PrEP to remain of
benefit, considering increased exposure to STIs, across a
range of possible attained PrEP effectiveness levels.
Data and model parameterization
The HIV-risk equations were parameterized using sexual
behaviour data from Hillbrow, Johannesburg collected by
WRHI, as well as biological and epidemiological data from
other literature (Supplementary Methods: Table S1). As
there is uncertainty about the PrEP effectiveness corre-
sponding to levels of drug adherence, calculations were
carried out for a range of simulated values of PrEP effec-
tiveness for a given adherence value (bα). The values simu-
lated roughly span the range of risk reduction estimated
through the iPrEx OLE [7] study (between 44% correspond-
ing to fewer than 2 tablets a week and 100% corresponding
to at least 4 tablets a week). We started from a slightly
lower baseline of 35% to reflect, conservatively, that this
study was conducted in a different study population.
It was assumed that all sex acts are peno-vaginal on the
basis of available epidemiological data for FSWs in Hillbrow
[46]. Three months was chosen as the period of HIV-risk
evaluation, as this corresponds to the period after which an
HIV test must be performed on PrEP to check for serocon-
version (amongst other indicators) [34,48].
Sensitivity analysis
Two categories of sensitivity analysis were performed. First,
the calculations were repeated for two boundary cases:
high risk (HR) and low risk (LR) FSWs, parameterized using
high- and low-risk values in the HIV-risk equation for the
sexual behaviour parameters (% partners HIV positive,
number of partners and average number of sex acts per
three months, probability at least one person in the part-
nership has an STI) and the transmission probability para-
meters (condom HIV-risk reduction efficacy, probability of
HIV transmission through peno-vaginal sex, multiplicative
increase in per sex act probability of HIV transmission in the
presence of an STI).
A second set of sensitivity analyses were undertaken to
explore the case that any condom migration brings with it
increases in STI prevalence, and therewith risk of HIV trans-
mission. In spite of high levels of STI treatment in the FSW
population [49], to obtain conservative results in terms of
change in condom consistency tolerated following the intro-
duction of PrEP, we assumed that STIs are present in all
partnerships where reductions in condom consistency occur,
and that these STIs are transmitted through the sex act if not
already present in both partners. The probability that at least
one person in the partnership has an STI following the intro-
duction of PrEP is therefore assumed to increase at the same
rate as the change in condom consistency.
Results
Single partner population
We deduced that where the level of PrEP effectiveness
achieved equals or exceeds that of condoms (i.e. condom
efficacy * baseline condom consistency), PrEP will be of
equal or greater benefit in reducing HIV risk and therefore
condom use could be reduced to zero without HIV risk
increasing. Where the level of PrEP effectiveness is less
than the effectiveness originally achieved with condoms,
we see that greater drops in condom consistency can be
tolerated for those FSW with lower baseline condom
consistencies.
Figure 1 shows the break-even condom consistency after
introduction of PrEP such that HIV risk is not increased.
Large relative reductions in condom consistency on PrEP
are anticipated to be especially well tolerated where higher
levels of PrEP effectiveness achieved (>65%). For FSWs
whose baseline consistencies are low (<55%), or where
there is not anticipated to be a large relative drop in
condom consistency on PrEP, even the achievement of
low levels of PrEP effectiveness will reduce HIV risk.
Single partner population, accounting for increased STI
exposure
The results show that reductions in condom consistency on
PrEP are especially well tolerated for FSWs with lower
baseline condom consistencies (<50%) and where higher
levels of PrEP effectiveness are achieved (>65%). Even for
the lowest level of 35% PrEP effectiveness simulated (which
would correspond to adherence to fewer than two tablets a
week according to iPrEx OLE [7] estimates), the percentage
reduction in condom consistency tolerated steadily
increases upwards from a minimum reduction of 17% (cor-
responding to 90% baseline condom consistency) to 100%
migration (corresponding to 30% baseline condom
consistency).
Where PrEP effectiveness of 85% can be achieved (which
would correspond to adherence of 2–3 tablets a week
according to iPrEx OLE [7] estimates; and the exact level
of assumed condom protection efficacy simulated for the
base case), 100% condom migration can uniformly be tol-
erated across all baseline condom consistencies simulated.
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The percentage change in condom consistency possible is
almost the same (<1% difference) whether STIs are
accounted for or not in the HIV-risk equations
(Supplementary Results: Table S2, shown graphically in
Figure 2). This is because, whilst inclusion of STI parameters
in the mathematical HIV-risk equations does result in
increased HIV risk levels on an absolute basis, it does not
significantly affect change in risk on a relative basis.
Sensitivity analysis
Looking at the boundary cases of high- and low-risk FSW
reveals only small variations in the percentage reduction in
condom consistency tolerated (accounting for STIs or not in
the equations). This is especially true at lower levels of PrEP
effectiveness and higher baseline condom consistencies (4–
8% reduced reduction in condom consistency tolerated),
although this is slightly more pronounced at higher levels
of PrEP effectiveness (up to 22% reduced reduction).
Should condom migration brings with it increases in STI
prevalence in the population, there would be modest
reductions in the percentage reduction in condom consis-
tency tolerated (at most 22% reductions in relative terms
compared to the base case results, or between 2 and 20%
less in absolute terms), though the differences in the results
are smaller especially where PrEP effectiveness achieved is
lower (<65%) and initial condom consistency is high (>70%),
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Figure 1. Break-even condom consistencies following introduction of PrEP.
In the case of a single partner population, the figure describes the break-even condom consistencies (the levels that condom use could be
reduced to, following introduction of PrEP) such that HIV risk is not increased on PrEP. These break-even levels are shown for baseline
condom consistencies between 30% and 100%, and corresponding to six different levels of achieved PrEP effectiveness ranging from 35% to
85% (85% corresponding to the level of condom efficacy assumed in this study).
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Figure 2. Percentage reduction in condom consistency tolerated with a single partner population for HIV risk not to increase on PrEP,
accounting for the effect of STIs on HIV risk.
For different baseline condom consistencies between 30 and 95%, the figure describes the percentage reduction in condom consistency that
could be tolerated on PrEP corresponding to six different levels of achieved PrEP effectiveness, ranging from 35 to 85% (85% corresponding
to the level of condom efficacy assumed in this study).
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or where PrEP effectiveness achieved is higher (  65%)
and initial condom consistency is below ~80%.
Two partner populations, accounting for increased STI
exposure
Table 1 demonstrates the percentage reductions in condom
consistency with clients tolerated to achieve 50 or 90%
levels of reduction in HIV risk on PrEP, condom consistency
with regular partners held constant (at 10% [50]).
Achievement of 50% reduction in HIV risk on PrEP is
feasible across all simulated PrEP effectiveness levels (55,
75, 95%) and baseline condom consistencies (30–90%). As
seen for single partner populations, reductions in condom
consistency are best tolerated for FSWs with lower baseline
levels with clients or where higher PrEP effectiveness levels
are achieved.
A FSW with initial condom consistency of 30% with
clients could reduce her consistency by one-third and still
achieve 50% reduction in HIV risk, if she were able to attain
55% PrEP effectiveness (corresponding to below 2–3 doses
a week per iPrEx OLE [7]). A FSW achieving 95% PrEP
effectiveness (corresponding to around 4 doses a week
per iPrEx OLE [7]) could tolerate 100% condom migration
to achieve HIV risk reductions in excess of 50%; and so too
for those FSWs achieving 75% PrEP effectiveness for base-
line condom consistencies with clients of up to 70%.
Across the parameters simulated, the higher level of 90%
risk reduction on PrEP could only be achieved in the case
where PrEP is 95% effective (corresponding to around 4
doses a week per iPrEx OLE [7]). In this case, an initially
90% condom-consistent FSW could reduce her condom use
with clients by more than half; and for FSWs with baseline
condom consistencies with clients of 70% and lower, 100%
condom migration on PrEP could be tolerated.
Again, there is negligible observable (<1%) difference
whether or not STIs are accounted for in the HIV risk
equations.
In the case that PrEP leads to full condom migration with
regular partners, rather than remaining consistent at 10%,
there is a small further reduction in condom consistency
tolerated (between 1 and 8% across the scenarios simu-
lated, see Supplementary Results Table S4)).
Sensitivity analysis
Looking at the boundary cases of high- and low-risk FSW
reveals small variation in the percentage reduction in con-
dom consistency tolerated for the lower level of PrEP effec-
tiveness of 55%. The variation is more pronounced for higher
levels of PrEP effectiveness (75 and 95%), with up to around
one-third change in percentage reduction in condom consis-
tency tolerated across the parameter ranges simulated.
In the case that condom migration brings with it
increases in STI prevalence in the population, there are
reductions in relative terms of 14–26% compared to the
base case results, and in absolute terms the reductions are
almost uniformly within the range of variation seen through
examining the boundary cases of high- and low-risk FSW.
Discussion
This study provides insights into the risks associated with
condom migration following the introduction of PrEP into a
comprehensive HIV prevention programme for FSWs. The
study demonstrates that the success of PrEP will rest upon
its ability to achieve high enough PrEP adherence in FSWs
such that the increased protection achieved outweighs the
increased HIV risk owing to condom migration and increased
STIs exposure. The added value for decision makers of our
study lies upon our ability to quantify these trade-offs.
This study has demonstrated that where a FSW’s adher-
ence to PrEP achieves a level of effectiveness that exceeds
that of condoms, PrEP will always reduce HIV risk. Condom
migration is anticipated to be especially well tolerated where
baseline levels of condom consistency are low (<50%) or
where a reasonably high level of PrEP effectiveness (>65%)
can be achieved. Should FSWs’ condom consistency with
regular partners remain low (~10%) or be reduced to zero
on PrEP, reductions in condom consistency with clients could
uniformly be tolerated whilst still achieving 50% HIV-risk
reduction (assuming achieved PrEP effectiveness of at least
55%). This is especially noteworthy having considered prob-
abilities of up to 60% likelihood of STI exposure in a partner-
ship if condom migration were to occur.
From a programming point of view, strategies to identify
FSWs with initially higher condom-consistent behaviour but
anticipated to adhere less well to PrEP will be important,
and efforts to promote condom consistency and give adher-
ence support critical. Considering that full condom migra-
tion with regular partners does not substantially increase
HIV risk on PrEP (assuming initially low consistency with
regular partners holds true), efforts to encourage condom
consistency with clients will be critical.
The study has demonstrated that the break-even point at
which PrEP is beneficial in terms of HIV-risk reduction is
driven primarily by the behavioural parameters of condom
consistency and drug adherence, as well as by the efficacy
of condoms, and much less by epidemiological parameters.
This is noteworthy in programme design, as efforts to
improve and sustain behaviours relating to PrEP adherence
and condom consistency will have the greatest influence on
programme outcomes over epidemiologic context.
There are, however, a number of caveats to the study.
This work does not speak to acceptable PrEP adherence
levels, given the risk of ARV resistance, noting that PrEP
users in the middle adherence spectrum are anticipated to
be at greatest risk [51]. This study does not account for a
partner’s stage of HIV infection or ARV use in partner
populations. The former may increase HIV risk if partners
are likely to be recently infected and thus highly viremic,
whereas the latter would likely decrease overall risk; how-
ever, neither would be expected to impact comparative
estimates of change in HIV risk.
Use of a static rather than dynamic model limits the study
to an analysis of FSW HIV risk in isolation of the dynamics of
infections between FSWs, their partners and clients and in
turn to FSWs. These results, whilst suitable to indicate rules
of thumb to guide HIV prevention efforts, cannot provide
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Table 1. Maximum tolerated % reduction in condom consistency with clients (consistency with regular partners held constant) to still achieve 50% or 90% reductions in HIV risk
on PrEP, for different levels of PrEP effectiveness achieved
55% PrEP Effectiveness 75% PrEP Effectiveness 95% PrEP Effectiveness
% reduction in condom consistency with clients tolerated to get overall HIV risk reduction of
50% 90% 50% 90% 50% 90%
Accounting for
STIs
Not accounting for
STIs
Accounting for
STIs
Not accounting
for STIs Accounting for STIs
Not accounting for
STIs
Accounting for
STIs
Not accounting
for STIs
Accounting for
STIs
Not accounting
for STIs Accounting for STIs
Not accounting
for STIs
Initial condom consistency Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR)
90% 6% (−3%,-3%) 6% (−3%, 3%) - - - - 57% (−27%, 26%) 57% (−28%, 39%) - - - - 100% (*,*) 100% (*,*) 56% (−27%,19%) 57% (−28%,37%)
80% 8% (−3%,-5%) 8% (−3%,2%) - - - - 76% (−31%,24%) 77% (−31%, 23%) - - - - 100% (*,*) 100% (*,*) 75% (−29%,20%) 76% (−31%,24%)
70% 10% (−3%,-6%) 11% (−4%,2%) - - - - 100% (*,*) 100% (*,*) - - - - 100% (*,*) 100% (*,*) 100% (*,*) 100% (*,*)
50% 18% (−4%,-13%) 19% (−5%,2%) - - - - 100% (*,*) 100% (*,*) - - - - 100% (*,*) 100% (*,*) 100% (*,*) 100% (*,*)
30% 37% (−6%,-29%) 38% (−7%,0%) - - - - 100% (*,*) 100% (*,*) - - - - 100% (*,*) 100% (*,*) 100% (*,*) 100% (*,*)
For each level of PrEP effectiveness demonstrated, the table shows the % reduction in condom consistency that could be tolerated, from varying levels of initial condom consistency, to achieve
either 50% or 90% HIV-risk reduction. The results are shown for both the case that STIs are accounted for in the HIV risk equations, as well as the case that they are not. The results are shown
for the base case parameterization of the model, as well as the boundary cases explored through the first sensitivity analysis of high- and low-risk FSW. They assume that condom consistency
with regular partners remains constant at 10% before and after introduction of PrEP. The results corresponding to the case that condom consistency with regular partners drops from 10% to 0%
following the introduction of PrEP is shown in Table S4 in the Supplementary Materials.
“–” indicates that achievement of the risk reduction is not possible. “*” indicates full migration will still result in higher levels of risk reduction. “Base” refers to the main calculated results
undertaken using the baseline parameter values. HR stands for high risk and LR stands for low risk FSW, and the results calculated in the sensitivity analysis for the boundary parameter cases. A
graphic depiction of the results corresponding to achievement of 50% HIV risk reduction on PrEP is given in Supplementary Equations, Figure S1.
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insight into the downstream impact of the intervention and
condom migration on the HIV epidemic in South Africa.
Finally, the data used to characterize the FSW population in
Hillbrow are limited by being self-reported (susceptible to
underreporting) and age, as little has been published since
the end of the 1990s, when the HIV epidemic was less
evolved [52], although studies are underway.
Most importantly, this study indicates that, assuming oral
PrEP is proven effective in FSW populations through
ongoing trials, in many situations oral PrEP is likely to be
of benefit in reducing HIV risk even if behaviour change
were to be a programme reality. It provides guidance
around the characteristics of FSWs for whom condom
migration may be more of an issue (those with initially
high levels of condom consistency with clients, anticipated
to adhere poorly to PrEP and significantly migrate away
from condoms); and those FSWs for whom PrEP is likely
to be an important addition to combined HIV prevention
measures (those with initially low condom consistency with
clients, or anticipated to adhere reasonably well to PrEP).
Importantly for the latter group, PrEP will provide addi-
tional protection against HIV transmission from regular
partners, with whom there is otherwise little protection
given low baseline condom levels. Finally, the analytic
approach followed in this study could easily be adapted to
other vulnerable populations beyond FSW.
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